Amaurosis fugax
Definition
Amaurosis fugax is a temporary loss of vision in one or both eyes due to a lack of blood flow to the retina. The retina is the light-sensitive layer of tissue at the back of the eyeball.
Alternative Names
Transient monocular blindness; Transient monocular visual loss; TMVL; Transient monocular visual loss; Transient binocular visual loss; TBVL; Temporary visual loss - amaurosis fugax
Causes
Amaurosis fugax is not itself a disease. Instead, it is a sign of other disorders. Amaurosis fugax can occur from different causes. One cause is when a blood clot or a piece of plaque blocks an artery in the eye. The blood clot or plaque usually travels from a larger artery, such as the carotid artery in the neck or an artery in the heart, to an artery in the eye.
Plaque is a hard substance that forms when fat, cholesterol, and other substances build up in the walls of arteries. Risk factors include:
- Heart disease, especially irregular heartbeat
- Alcohol abuse
- Cocaine use
- Diabetes
- Family history of stroke
- High blood pressure
- High cholesterol
- Increasing age
- Smoking (people who smoke one pack a day double their risk for a stroke)
Amaurosis fugax can also occur because of other disorders such as:
- Other eye problems, such as inflammation of the optic nerve (optic neuritis)
- Blood vessel disease called polyarteritis nodosa
- Migraine headaches
- Brain tumor
- Head injury
- Multiple sclerosis (MS), inflammation of the nerves due to the body's immune cells attacking the nervous system
- Systemic lupus erythematosus, an autoimmune disease in which the body's immune cells attack healthy tissue throughout the body
Symptoms
Symptoms include the sudden loss of vision in one or both eyes. This usually lasts for a few seconds to several minutes. Afterward, vision returns to normal. Some people describe the loss of vision as a gray or black shade coming down over the eye.
Exams and Tests
Your health care provider will perform a complete eye and nervous system exam. In some cases, an eye exam will reveal a bright spot where the clot is blocking a retinal artery.
Tests that may be done include:
Treatment
Treatment of amaurosis fugax depends on its cause. When amaurosis fugax is due to a blood clot or plaque, the concern is to prevent a stroke. The following can help prevent a stroke:
- Avoid fatty foods and follow a healthy, low-fat diet. Do not drink more than 1 to 2 alcoholic drinks a day.
- Exercise regularly: 30 minutes a day if you are not overweight; 60 to 90 minutes a day if you are overweight.
- Quit smoking.
- Most people should aim for a blood pressure below 120 to 130/80 mm Hg. If you have diabetes or have had a stroke, your provider may tell you to aim for a lower blood pressure.
- If you have diabetes, heart disease, or hardening of the arteries, your LDL (bad) cholesterol should be lower than 70 mg/dL. Some experts recommend an even lower target, below 55 mg/dL.
- Follow your provider's treatment plans if you have high blood pressure, diabetes, high cholesterol, or heart disease.
Your provider may also recommend:
- No treatment. You may only need regular visits to check the health of your heart and carotid arteries.
- Aspirin, warfarin (Coumadin), or other blood-thinning medicines to lower your risk for stroke.
If a large part of the carotid artery appears blocked, carotid endarterectomy surgery is done to remove the blockage. The decision to do surgery is also based on your overall health.
Outlook (Prognosis)
Amaurosis fugax increases your risk for stroke.
When to Contact a Medical Professional
Contact your provider if any vision loss occurs. If symptoms last longer than a few minutes or if there are other symptoms with the vision loss, seek medical attention right away.
References
Biller J, Schneck MJ, Ruland S. Ischemic cerebrovascular disease. In: Jankovic J, Mazziotta JC, Pomeroy SL, Newman NJ, eds. Bradley and Daroff's Neurology in Clinical Practice. 8th ed. Philadelphia, PA: Elsevier; 2022:chap 65.
Brown GC, Sharma S, Brown MM. Ocular ischemic syndrome. In: Sadda SVR, Sarraf D, Freund KB, et al, eds. Ryan's Retina. 7th ed. Philadelphia, PA: Elsevier; 2023:chap 61.
Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2022 ACC expert consensus decision pathway on the role of nonstatin therapies for LDL-Cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2022;80(14):1366-1418. PMID: 36031461 pubmed.ncbi.nlm.nih.gov/36031461/.
Review Date:
6/13/2024
Reviewed By:
Joseph V. Campellone, MD, Department of Neurology, Cooper Medical School at Rowan University, Camden, NJ. Review provided by VeriMed Healthcare Network. Also reviewed by David C. Dugdale, MD, Medical Director, Brenda Conaway, Editorial Director, and the A.D.A.M. Editorial team.
The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. A licensed medical professional should be consulted for diagnosis and treatment of any and all medical conditions. Links to other sites are provided for information only -- they do not constitute endorsements of those other sites. No warranty of any kind, either expressed or implied, is made as to the accuracy, reliability, timeliness, or correctness of any translations made by a third-party service of the information provided herein into any other language. © 1997-
A.D.A.M., a business unit of Ebix, Inc. Any duplication or distribution of the information contained herein is strictly prohibited.
© 1997-
All rights reserved.
A.D.A.M. content is best viewed in IE9 or above, Firefox and Google Chrome browser.